SARS-COV-2, A NEW ETIOLOGICAL AGENT OF GUILLAIN-BARRE SYNDROME: A CASE REPORT
DOI:
https://doi.org/10.61841/z33gz644Abstract
Guillain-Barre syndrome (GBS) is an acute progressive polyradiculoneuropathy where body’s immune system mistakenly attacks the peripheral nerves and their spinal roots.Covid 19 is a highly contagious disease declared as a global pandemic in 2020. We report a case of GBS in asymptomatic non vaccinated ( against novel corona virus) covid 19 patient. A 18 years old male patient with no co morbidities admitted with 2 days history of sudden onset weakness of all four limbs. He was tested covid 19 RTPCR positive with no previous history of any symptoms of covid 19. His anti SARS COV2 antibody was positive. Nerve conduction velocity study showed severe acute motor neuropathy. He was electively intubated and ventilated, successfully treated with intravenous immunoglobulins. We conclude SARS COV2 can induce immune system without any prodomal symptoms, so we should aware about SARS COV 2 as an etiological agent of GBS.
References
Helm J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. New England Journal of Medicine. 2020; NEJMc2008597. https://doi.org/10.1056/NEJMc2008597
Carod-Artal FJ. Neurological complications of coronavirus and COVID-19. Revista de Neurología. 2020; 70(9):311–322. https://doi.org/10.33588/rn.7009.2020179
Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. The Lancet. 2016; 388(10045):717–727.
Alberti P, Beretta S, Piatti M, et al. Guillain-Barré syndrome related to COVID-19 infection. Neurology: Neuroimmunology & Neuroinflammation. 2020; 7:e741. https://doi.org/10.1212/NXI.0000000000000741
Virani A, Rabold E, Hanson T, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection. IDCases. 2020; 20:e00771. https://doi.org/10.1016/j.idcr.2020.e00771
Sedaghat Z, Karimi N. Guillain-Barré syndrome associated with COVID-19 infection: a case report. Journal of Clinical Neuroscience. 2020; 76:233–235. https://doi.org/10.1016/j.jocn.2020.04.062
Camdessanche JP, Morel J, Pozzetto B, Paul S, Tholance Y, Botelho-Nevers E. COVID-19 may induce Guillain-Barré syndrome. Revue Neurologique (Paris). 2020; 176:516–518. https://doi.org/10.1016/j.neurol.2020.04.003
Padroni M, Mastrangelo V, Asioli GM, et al. Guillain-Barré syndrome following COVID-19: new infection, old complication? Journal of Neurology. 2020; 267:1877–1879. https://doi.org/10.1007/s00415-020-09849-6
Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. Journal of Clinical Virology. 2020; 127:104362.
Qu J, Wu C, Li X, et al. Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases. 2020; 71(16):2255–2258.
Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barré syndrome associated with SARS-CoV-2. New England Journal of Medicine. 2020; 382:2574–2576. https://doi.org/10.1056/NEJMc2009191
Scheidl E, Canseco DD, Hadji-Naumov A, Bereznai B. Guillain-Barré syndrome during SARS-CoV-2 pandemic: a case report and review of recent literature. Journal of the Peripheral Nervous System. 2020; 25:204–207. https://doi.org/10.1111/jns.12382
Araújo NM, Ferreira LC, Dantas DP, et al. First report of SARS-CoV-2 detection in cerebrospinal fluid in a child with Guillain-Barré syndrome. Pediatric Infectious Disease Journal. 2021; 40(7):e274–e276. https://doi.org/10.1097/INF.0000000000003146
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Dr Dilip Kumar Singri, Dr. Ujjwal Mondal, Dr. Anirban Kumar Ghosh, Dr. Rajashish Majumder (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
